A Phase 4 interventional study of AD-4833 15 mg and AD-4833 30 mg in Diabetes Mellitus, sponsored by Takeda. Completed at 25 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-08-31.
Sponsored by Takeda · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing pioglitazone in Diabetes Mellitus — 4 open to participants now, 4 under way, none of them phase 3. Pioglitazone · Diabetes Mellitus.
Among the 57 studies testing pioglitazone in Diabetes Mellitus, this one is the 21st largest by enrollment of the 55 interventional ones that give a count, is the only one that started in 2012, is one of 22 in phase 4, and was the 48th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →4 of the 57 studies testing pioglitazone in Diabetes Mellitus are open now, in 2 countries. Recruiting first, the newest first:
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
By country, each count listing its studies:
Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 11 · Phase 3 16 · Phase 4 22
First in 2000; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 207 is above the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 104 across the 55 interventional studies. Of the 50 that completed or were terminated, 15 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 57 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
71 studies in Diabetes Mellitus by Takeda: none open now, none under way, none of them phase 3. Of 71 finished, 35 (49%) have results posted.
Among the 71 studies in Diabetes Mellitus by Takeda, this one is the 46th largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2012, is one of 7 in phase 4, and was the 64th registered.
Takeda’s Diabetes Mellitus studies by the year they started, since 1997.
1 of the studies testing pioglitazone in Diabetes Mellitus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06729996Mayo ClinicPioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 57 studies testing pioglitazone in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 71 in Diabetes Mellitus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AD-4833 15 mg
Drug: AD-4833 30 mg
Drug: Placebo
Glycosylated Hemoglobin (HbA1c)
Measurement of change in HbA1c (ratio of hemoglobin bound to glucose)
Time frame: 16 weeks
The record gives a start of Sep 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pioglitazone